Venom Immunotherapy (VIT)

Albey® and Hymenoptera® venom product supply updates

March 2025: Re-supply of registered ALBEY® venom products in Australia from Q2 2025

Stallergenes Greer will be starting to re-establish the supply of registered ALBEY® brand venom products (Honey Bee, Paper Wasp, Yellow Jacket) in Australia. These will replace the equivalent unregistered HYMENOPTERA® brand venom products (Honey Bee, Paper Wasp, Yellow Jacket) currently supplied under a S19A exemption.

HYMENOPTERA® and ALBEY® venom products are all PBS reimbursed and patient contributions will remain the same after the transition to ALBEY®.

Timing of supply

The first supply of ALBEY® products will occur between 2025 and 2026.
This transition from HYMENOPTERA® to ALBEY® venom products in Australia is managed under an arrangement with the Australian Department of Health and Aged Care, with ALBEY® products to be supplied once stocks of HYMENOPTERA® products are depleted.
The exact timing of the “switch over” for each allergen will differ, according to when existing stocks of HYMENOPTERA® products are depleted.
Stallergenes Greer will communicate the exact timing of the switch to ALBEY® for each allergen, once confirmed (see the summary of expected supply dates below).

Equivalence of products

HYMENOPTERA® and ALBEY® venom products are identical in terms of the drug substance,materials, equipment and method of manufacture of the drug substance and the finished product, as well as the immediate container and closure.
Reflecting this equivalence, patients receiving maintenance therapy may be considered to continue maintenance therapy when switching from HYMENOPTERA® to ALBEY®*

Product presentation

Registered ALBEY® products will be re-supplied in exactly the same presentation as in the past, containing 1 x 550 microgram powder for injection vial with 1 x 9 ml albumin diluent vial (for the preparation of the maintenance dose) and also including 3 x 1.8 ml albumin diluent vials (for the preparation of initiation doses), which are supplied separately for HYMENOPTERA® products:

ALBEY® BEE VENOM Honey Bee venom (550 microgram powder for injection vial with 4 vials of Albumin saline diluent; 1 x 9 ml + 3 x 1.8 ml)
ALBEY® PAPER WASP VENOM Paper Wasp venom (550 microgram powder for injection vial with 4 vials of Albumin saline diluent; 1 x 9 ml + 3 x 1.8 ml)
ALBEY® YELLOW JACKET VENOM Vespula spp venom (550 microgram powder for injection vial with 4 vials of Albumin Saline Diluent; 1 x 9 ml + 3 x 1.8 ml)

Orders / prescriptions

Continue to place orders / prescriptions for HYMENOPTERA® until further notice on the specific dates to start placing orders / prescriptions ALBEY® for each allergen.
Stallergenes will communicate the exact timing of the switch to ALBEY® for each allergen, once confirmed (see the summary of expected supply dates below).
Once ALBEY® products are in supply, customers with unprocessed orders for HYMENOPTERA® products will be contacted by DHL Customer Service to amend their purchase orders to switch the order to ALBEY® product codes and prices (only amended orders will be processed and dispatched.

Current expected supply dates:

ALBEY® YELLOW JACKET VENOM Vespula spp venom - April 2025
ALBEY® BEE VENOM Honey Bee venom - Q2 2025
ALBEY® PAPER WASP VENOM Paper Wasp venom - Q2 2026

For assistance with any questions related to the change from HYMENOPTERA® venom products to ALBEY® venom
products, please contact Customer Service Coordinator: Billy Harvey-Anderson +61 420 377 389 or
This email address is being protected from spambots. You need JavaScript enabled to view it.

For assistance with current or future venom orders, contact your Stallergenes Greer Territory Manager:
NSW South / QLD Henry Tangi This email address is being protected from spambots. You need JavaScript enabled to view it.
NSW North/ ACT John Seeto This email address is being protected from spambots. You need JavaScript enabled to view it.
VIC / TAS Daniella Samaila This email address is being protected from spambots. You need JavaScript enabled to view it.
WA / SA Aida Da Silva This email address is being protected from spambots. You need JavaScript enabled to view it.

For medical information enquiries, please contact APAC Regional Medical Director, Dr Martin Rees
This email address is being protected from spambots. You need JavaScript enabled to view it.

To report adverse events, email This email address is being protected from spambots. You need JavaScript enabled to view it.

September 2022: Hymenoptera® venom products

The full range of Hymenoptera® venom products (Honey Bee, Paper Wasp and Yellow Jacket) are available from Stallergenes Greer in Australia and New Zealand. This is due to the continued supply from the manufacturer of Hymenoptera venom products (Jubilant HollisterStier LLC).

For assistance with venom orders, contact your Stallergenes Greer territory manager.

Registered and replacement venom products: differences in external appearance

Stallergenes Greer is continuing efforts to secure the supply of registered ALBEY® venom products. Replacement Hymenoptera® venom products and replacement sterile Greer diluents (which are both FDA registered products in the US) have been authorised by the TGA for supply in Australia under S19A(1) of the Therapeutic Goods Act and New Zealand under S26 of the Therapeutic Goods Act.

Whilst the external appearance of the replacement products and registered products differ, they are identical in terms of the:

drug substance and materials;
equipment and method of manufacture of drug substance and finished product; and
immediate container and closure.

The registered and replacement products are both delivered from the manufacturer in sterile vials within tamper-evident packaging: e.g. within sealed external plastic packaging in the case of the replacement Greer diluents, and within vials with breakable caps in the case of the registered ALBEY® diluents. In the case of the replacement Greer diluents, the Certificate of Conformance released by Greer Quality Assurance is available here:

Certificate of Conformance - Albumine-Saline Diluent 9mL x25 Batch 350890.pdf255.74 KB

This document confirms that the products supplied as detailed above have passed all test requirements (e.g. sterility) and have met all defined product specifications required by the FDA.

If you remove these products from their original tamper-evident packaging to provide to third parties for administration, please explain the difference in the external appearance of the product and refer to this communication if necessary.

Stallergenes Greer understands the impact of this shortage on both patients and prescribers and are committed to ensuring reliable supply of these important products into Australia and New Zealand on an ongoing basis. We will provide further updates as soon as more information is available.

In case of future shortages, for guidance on how to make decisions about the appropriate care for patients currently receiving venom immunotherapy, and measures to avoid interruptions to therapy in high-risk patients, you may wish to refer to the following websites: